

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 74903

**Title:** Immunotherapy for Nonalcoholic Fatty Liver Disease-related Hepatocellular Carcinoma: Lights and Shadows

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 03725657

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Doctor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2022-03-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-03-19 21:24

**Reviewer performed review:** 2022-03-20 00:45

**Review time:** 3 Hours

Scientific quality	[ <input checked="" type="radio"/> ] Grade A: Excellent [ <input type="radio"/> ] Grade B: Very good [ <input type="radio"/> ] Grade C: Good [ <input type="radio"/> ] Grade D: Fair [ <input type="radio"/> ] Grade E: Do not publish
Language quality	[ <input checked="" type="radio"/> ] Grade A: Priority publishing [ <input type="radio"/> ] Grade B: Minor language polishing [ <input type="radio"/> ] Grade C: A great deal of language polishing [ <input type="radio"/> ] Grade D: Rejection
Conclusion	[ <input checked="" type="radio"/> ] Accept (High priority) [ <input type="radio"/> ] Accept (General priority) [ <input type="radio"/> ] Minor revision [ <input type="radio"/> ] Major revision [ <input type="radio"/> ] Rejection
Re-review	[ <input checked="" type="radio"/> ] Yes [ <input type="radio"/> ] No

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="radio"/> ] Anonymous [ <input type="radio"/> ] Onymous
	Conflicts-of-Interest: [ <input type="radio"/> ] Yes [ <input checked="" type="radio"/> ] No

## SPECIFIC COMMENTS TO AUTHORS

Comments to authors Authors wrote the manuscript entitled ‘Immunotherapy for Nonalcoholic Fatty Liver Disease-related Hepatocellular Carcinoma: Lights and Shadows’. This manuscript is interesting, but has some concerns and needs revision to be acceptable.

1. Authors cited the reference 94 and discussed the reason why the underlying liver diseases affect the tumor response to immunotherapy. What do you think about relationship between the treatment method (ICI monotherapy, combination with ICI and anti-VEGF agents, and ICI + ICI therapy) and etiology of liver diseases? Please authors discuss it more details.
2. Please authors cited following real-world data concerning the sorafenib (PMID: 34693661) and lenvatinib (PMID: 34515171), and discuss it. In addition, according to the reference 94 (PMID: 34847382), there are significant differences in patient characteristics at baseline between the NASH correlate- and no NASH correlate-patients, leading to possibly significant bias. I believed that citing reference 94 is not suitable for your manuscript.

## PEER-REVIEW REPORT

**Name of journal:** *World Journal of Gastrointestinal Oncology*

**Manuscript NO:** 74903

**Title:** Immunotherapy for Nonalcoholic Fatty Liver Disease-related Hepatocellular Carcinoma: Lights and Shadows

**Provenance and peer review:** Invited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer's code:** 05387164

**Position:** Editorial Board

**Academic degree:** MD, PhD

**Professional title:** Associate Professor

**Reviewer's Country/Territory:** Japan

**Author's Country/Territory:** Italy

**Manuscript submission date:** 2022-03-18

**Reviewer chosen by:** AI Technique

**Reviewer accepted review:** 2022-03-19 02:45

**Reviewer performed review:** 2022-03-21 22:06

**Review time:** 2 Days and 19 Hours

<b>Scientific quality</b>	<input type="checkbox"/> Grade A: Excellent <input checked="" type="checkbox"/> Grade B: Very good <input type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
<b>Language quality</b>	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
<b>Conclusion</b>	<input type="checkbox"/> Accept (High priority) <input type="checkbox"/> Accept (General priority) <input checked="" type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
<b>Re-review</b>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No



**Baishideng  
Publishing  
Group**

7041 Koll Center Parkway, Suite  
160, Pleasanton, CA 94566, USA  
**Telephone:** +1-925-399-1568  
**E-mail:** bpgoffice@wjgnet.com  
<https://www.wjgnet.com>

<b>Peer-reviewer statements</b>	Peer-Review: [ <input checked="" type="checkbox"/> ] Anonymous [ <input type="checkbox"/> ] Onymous Conflicts-of-Interest: [ <input checked="" type="checkbox"/> ] Yes [ <input type="checkbox"/> ] No
-------------------------------------	---

#### **SPECIFIC COMMENTS TO AUTHORS**

Dear author Thank you for the submission of your article to our journal. In enjoyed your paper and felt your paper should be very informative to many readers except for the problems described below. 1. You should avoid paragraphs with only one sentence, except for paragraphs that state the purpose of the introduction. 2. You should avoid using the same relative pronoun in a sentence such as “which is a M1 phenotype marker which is associated with macrophage-dependent T-cells activation and favorable prognosis in several cancers[50].” 3.P16 English expression “in which PD-L1 is involved limits is usefulness” is strange.